Department of Life Sciences, School of Science, University of Management and Technology, Lahore, Pakistan.
Centre for Applied Molecular Biology, University of the Punjab, Lahore, Pakistan.
J Med Virol. 2019 Mar;91(3):514-517. doi: 10.1002/jmv.25319. Epub 2018 Oct 17.
Thyroid dysfunctions occur frequently among hepatitis C virus (HCV)-infected patients. Accumulating evidence has shown the higher incidence of thyroid dysfunctions in interferon-treated patients that was previously the standard of care therapy. However, the prevalence of thyroid disorders has not been studied in the recently developed interferon-free regimens or direct-acting antiviral (DAA) drugs-treated patients. We recruited 37 patients who had just completed 6 months long sofosbuvir-based treatment, and 26 interferon-treated patients were also included in the study. Serum thyrotropin level of all participants was measured using VIDAS. We observed thyroid dysfunctions in both pegylated interferon-experienced and DAA drug-experienced patients but the prevalence of hyperthyroidism was found significantly higher in patients treated with interferon-based regimen as compared with interferon-free regimens. This high prevalence of hypothyroidism in patients with HCV posttreatment highlights the need for regular periodic screening of patients during the treatment.
丙型肝炎病毒 (HCV) 感染患者常发生甲状腺功能障碍。越来越多的证据表明，在干扰素治疗的患者中，甲状腺功能障碍的发生率更高，这是以前的标准治疗方法。然而，在最近开发的无干扰素方案或直接作用抗病毒 (DAA) 药物治疗的患者中，尚未研究甲状腺疾病的患病率。我们招募了 37 名刚刚完成 6 个月索磷布韦治疗的患者，同时也纳入了 26 名干扰素治疗的患者。所有参与者的血清促甲状腺激素水平均采用 VIDAS 进行测量。我们观察到聚乙二醇干扰素治疗和 DAA 药物治疗经验的患者均存在甲状腺功能障碍，但与无干扰素方案相比，基于干扰素方案治疗的患者中甲亢的患病率明显更高。丙型肝炎病毒治疗后患者发生甲状腺功能减退症的高患病率突出表明，在治疗期间需要定期对患者进行筛查。
